Rifampicin Resistance Detection
Rifampicin Resistance Detection - Related Videos
11:56
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
0 Views •
Cited by 4 •
2013
Acquired resistance to antibiotics is a major public healthcare problem and is presently ranked by the WHO as one of the greatest threats to human life. Here we describe the use of cantilever technology to quantify antibacterial resistance, critical to the discovery of novel and powerful agents against multidrug resistant bacteria.
14:04
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
0 Views •
Cited by 17 •
2013
Lytic phage biosensors and antibody beads are able to discriminate between methicillin resistant (MRSA) and sensitive staphylococcus bacteria. The phages were immobilized by a Langmuir-Blodgett method onto a surface of a quartz crystal microbalance sensor and worked as broad range staphylococcus probes. Antibody beads recognize MRSA.
23:06
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
0 Views •
Cited by 33 •
2008
The microscopic-observation drug-susceptibility (MODS) assay is a low-cost, low-tech tool for high-performance detection of tuberculosis (TB) and multidrug-resistant tuberculosis (MDRTB). This video describes the MODS liquid media culture method.
09:58
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
0 Views •
Cited by 25 •
2016
Here we describe a protocol aimed at investigating the impact of aberrant splicing on drug resistance in solid tumors and hematological malignancies. To this goal, we analyzed the transcriptomic profiles of parental and resistant in vitro models through RNA-seq and established a qRT-PCR based method to validate candidate genes.
08:30
One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
0 Views •
Cited by 7 •
2012
The design of a straightforward one-day workflow scheme for bacterial pathogen diagnostics enables the rapid recognition of bloodstream infections. The inclusion of eight clinically relevant bacterial targets and their antibiotic resistance profiles offers the clinician an initial insight on the same day, which can lead to more adequate therapy.
FAQs
The rpoB gene encodes the β subunit of bacterial RNA polymerase, and resistance-associated mutations are often concentrated in its rifampicin-resistance-determining region. Molecular assays examine this region for genetic changes linked to the ability of Mycobacterium tuberculosis to withstand rifampicin. This makes rpoB analysis a focused way to identify a major mechanism of resistance.
Molecular tests identify resistance-associated mutations, providing genetic evidence that a strain may resist rifampicin. Phenotypic assays instead observe whether the organism grows during drug exposure, measuring the expressed resistance behavior. Comparing these approaches is valuable because genetic findings can be assessed alongside culture-based susceptibility results, helping confirm the interpretation of a resistance result.
Rifampicin is a key drug in tuberculosis treatment, so resistance to it can signal multidrug-resistant disease. Detecting that possibility quickly supports decisions about effective therapy rather than relying only on an assumed susceptible pattern. The result also has implications beyond an individual strain because resistant tuberculosis requires attention to transmission and infection-control concerns.
A molecular workflow provides information about whether resistance-associated changes, particularly in the rpoB rifampicin-resistance-determining region, are present. A phenotypic workflow provides evidence from growth under rifampicin exposure. Culture-based susceptibility testing can then contribute a confirming comparison. Together, these results help distinguish genetic evidence from observed drug response and support interpretation.
Comparison is important when molecular testing identifies a resistance-associated mutation or when the genetic result needs confirmation. Culture-based susceptibility testing evaluates growth under drug exposure, offering a phenotypic counterpart to the molecular result. This comparison can help confirm rifampicin resistance and support monitoring for resistance patterns that may emerge over time.
Rapid results can support timely treatment decisions for patients with potentially resistant tuberculosis. They also inform infection-control measures by identifying cases that may involve resistant strains, while accumulated findings contribute to surveillance of resistant tuberculosis. In Immunology and Infection research, this connects bacterial resistance testing with treatment response, transmission concerns, and population-level monitoring.